BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

DTx Leader Sidekick Enters Strategic Collaboration with Lilly to Support Patients with Breast Cancer

International digital therapeutics (DTx) innovator, Sidekick Health (www.sidekickhealth.com), today announces an integrated digital therape...

June 20, 2022 | News

Emmes Supports Groundbreaking Anal Cancer Study Sponsored by the National Cancer Institute

Emmes, a global, full-service clinical research organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovatio...

June 17, 2022 | News

Nonagen Bioscience announces CE mark for Oncuria® bladder cancer diagnostic

Oncuria is the first-of-its-kind multiplex urine test for the quantitative detection of 10 biomarkers in urine that are associated with the presence of...

June 17, 2022 | News

WuXi ATU and Wugen Announce Manufacturing Partnership to Expedite the Delivery of Novel Cell Cancer Immunotherapies

WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO), and Wugen Inc., a clinical-stage biotech...

June 16, 2022 | News

Telix and RefleXion Expand Partnership for Prostate Cancer Treatment

BgRT is the first and only cancer treatment designed to integrate PET technology as part of external-beam radiotherapy delivery. It uses PET tracers a...

June 13, 2022 | News

Prenetics Launches ColoClear, a Non-Invasive Stool DNA Test to Detect Early Signs of Colorectal Cancer in Hong Kong

Test sensitivity of 96% in colorectal cancer and 64% in advanced adenoma detection in clinical studies- ColoClear is the only cancer screening test ap...

June 09, 2022 | News

Leica Microsystems Open multiplexing with Cell DIVE offers cancer researchers more choices

Leica Microsystems, a leading provider of microscopy and scientific instruments, has introduced a new generation of its multiplexed imaging solution, Cell ...

June 08, 2022 | News

Everest Medicines' Licensing Partner Gilead Sciences Announces Positive Results from Phase 3 TROPiCS-02

Everest Medicines (HKEX 1952.HK) announces today that its licensing partner, Gilead Sciences, Inc. (Nasdaq: GILD), reported positive results from the prima...

June 06, 2022 | News

Merck Advances Development Programs in Oncology Focusing on Novel Mechanisms and Pathways

New data from DNA Damage Response (DDR) inhibitor portfolio inform development path for this promising biology Clinical trials in locally advanced head ...

June 06, 2022 | News

Novotech Sponsors Pre-ASCO China Summit Panels on Early Phase Oncology Trials, Regulatory Strategy for China and US

The Pre-ASCO Live Zoom series was watched by more than 20,000 people globally. The Novotech-sponsored panels, China CST 9:00-10:30 AM (May 14); US EST 9:00...

June 03, 2022 | News

Takeda Presents Latest Research from Oncology Portfolio and Pipeline at ASCO & EHA

Positive Results from the Phase 3 PARADIGM Study in Japanese Patients with Colorectal Cancer to be Presented During the Plenary Session at ASCO, in ...

June 02, 2022 | News

Indica Labs achieves CE-IVD certification for AI-based Prostate Cancer Detection and Gleason Grading Tool

Prostate cancer is the most common cancer diagnosed in men. With over 1.4 million cases reported worldwide in 2020, the incidence rates continue to rise wi...

June 01, 2022 | News

Boosting CAR-T cells with mRNA Vaccines: New Immunotherapy Strategy

One new strategy aiming to empower CAR T cells against solid tumors is the immunotherapy BNT211, which leverages a BioNTech’s mRNA lipoplex vaccine f...

May 30, 2022 | News

New Studies at ASCO 2022 Validate Effectiveness of Lunit AI as Diagnostic Aid in Cancer Treatment

New findings demonstrate the clinical efficacy of AI-powered tissue analysis as a guide in cancer treatment, according to medical AI provider Lunit. The fi...

May 30, 2022 | News

Stay Connected